Mikhail (Misha) V. Blagosklonny is a professor of oncology at Roswell Park Cancer Institute, located in Buffalo, NY. Mikhail Blagosklonny conducts research in molecular and cellular biology as well as engaging in clinical investigations. His areas of focus include:
-oncogenes and tumor suppressors
Regarding therapeutics, Mikhail Blagosklonny’s work emphasizes the application of science in strategic anticancer therapies that exploit the way cancer alters normal cell cycling. He also combats drug resistance by experimenting with the selective protection of normal cells. Other diseases related to aging have been approached using similar techniques, resulting in anti-aging drugs such as rapamycin.
Mikhail Blagosklonny is an extensive author in the theory of aging. He also writes on anti-cancer approaches known as cell cyclotherapy and chemotherapeutic engineering. His body of work includes 300 articles, reviews and book chapters. His publishing titles include:
-Editor-in-Chief, Cell Cycle
-Co-founder, Aging, Oncotarget and Oncoscience
-Associate Editor, International Journal of Cancer and The American Journal of Pathology
Blagosklonny studied at the First Pavlov State Medical University, located in St. Petersburg, and he received an M.D. in internal medicine and a doctorate in experimental medicine and cardiology at https://www.researchgate.net/profile/Mikhail_Blagosklonny. He first served as an associate professor at New York Medical College in Valhalla, NY before becoming a senior scientist at Ordway Research Institute in Albany, New York. In 2009, Blagosklonny became professor of oncology at Roswell Park, where he still teaches.
TOR Signaling in Aging and Cancer
Blagosklonny’s research on
Impact Journals interests have concentrated in cancer therapies, which protect normal cells from damage, and the causes of aging. He believes TOR signaling plays a role in both cancer and aging. Rapamycin is a cancer drug that may also help extend a patient’s lifespan.
Rapamycin is an mTOR inhibitor that helps regulate cell division and growth. When this process becomes dysfunctional, tumors such as cancer can occur. Rapamycin blocks the growth of tumors. This could even result in the death of tumor cells. Derivative drugs are in clinical trials as anti-cancer agents. These trials on tandfonline.com have suggested that mTOR inhibition can be used to target tumors without disrupting normal cell activities.
Blagosklonny is a determined advocate for rapamycin-based therapies.